PT - JOURNAL ARTICLE AU - Hanan Shaharuddin AU - Victoria Wang AU - Roberta S. Santos AU - Andrew Gross AU - Yizhou Wang AU - Harneet Jawanda AU - Yi Zhang AU - Wohaib Hasan AU - Gustavo Garcia, Jr. AU - Vaithilingaraja Arumugaswami AU - Dhruv Sareen TI - Deleterious effects of SARS-CoV-2 infection on human pancreatic cells AID - 10.1101/2021.02.01.21250846 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.01.21250846 4099 - http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250846.short 4100 - http://medrxiv.org/content/early/2021/02/03/2021.02.01.21250846.full AB - COVID-19 pandemic has infected more than 46 million people worldwide and caused more than 1.2 million deaths. It is transmitted by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and affects the respiratory tract as well as extra-pulmonary systems, including the pancreas, that express the virus entry receptor, Angiotensin-Converting Enzyme 2 (ACE2) receptor. Importantly, the endocrine and exocrine pancreas, the latter composed of ductal and acinar cells, express high levels of ACE2, which correlates to impaired functionality characterized as acute pancreatitis observed in some cases presenting with COVID-19. Since acute pancreatitis is already one of the most frequent gastrointestinal causes of hospitalization in the U.S. and the majority of studies investigating the effects of SARS-CoV-2 on the pancreas are clinical and observational, we utilized human iPSC technology to investigate the potential deleterious effects of SARS-CoV-2 infection on iPSC-derived pancreatic cultures containing endocrine and exocrine cells. Interestingly, SARS-CoV-2 is capable of infecting iPSC-derived pancreatic cells, thus perturbing their normal molecular and cellular phenotypes. The infection increased a key inflammatory cytokine, CXCL12, known to be involved in pancreas dysfunction. Transcriptome analysis of infected pancreatic cultures confirmed that SARS-CoV-2 hijacks the ribosomal machinery in these cells. Notably, the SARS-CoV-2 infectivity of the pancreas is confirmed in post-mortem tissues from COVID-19 patients, which showed co-localization of SARS-CoV-2 in pancreatic endocrine and exocrine cells and increased the expression of some pancreatic ductal stress response genes. Thus, we demonstrate for the first time that SARS-CoV-2 can directly infect human iPSC-derived pancreatic cells with supporting evidence of presence of the virus in post-mortem pancreatic tissue of confirmed COVID-19 human cases. This novel model of iPSC-derived pancreatic cultures will open new avenues for the comprehension of the SARS-CoV-2 infection and potentially establish a platform for endocrine and exocrine pancreas-specific antiviral drug screening.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe would like to acknowledge the support of the Cedars-Sinai Biomanufacturing Center facility and Cedars-Sinai Research Institute in supporting this project. This work was supported by Cedars-Sinai Programmatic Funds (DS). We would like to thank The David and Janet Polak Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. This research was also funded by UCLA DGSOM and Broad Stem Cell Research Center institutional award (OCRC #20-1) and (TRAN1COVID19-11975) to V.A. The following reagents were obtained through BEI Resources, NIAID, NIH: Polyclonal Anti-SARS Coronavirus (antiserum, Guinea Pig), NR-10361; The following reagent was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH: SARS-Related Coronavirus 2, Isolate USA-WA1/2020, NR-52281. We are grateful to Barbara Dillon, UCLA High Containment Program Director for BSL3 work. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Human cell lines, tissues and histology specimens were obtained or created at Cedars-Sinai under the auspices of the Cedars-Sinai Medical Center Institutional Review Board (IRB) approved protocols. Specifically, the iPSC cell lines and differentiation protocols in the present study were carried out in accordance with the guidelines approved by Stem Cell Research Oversight committee (SCRO) and IRB, under the auspices of IRB-SCRO Protocols Pro00032834 (iPSC Core Repository and Stem Cell Program) and Pro00036896 (Sareen Stem Cell Program). Infections of iPSC-derived cells were performed under the auspices of UCLA Stem Cell Oversight Committee under protocol 2020-004-01 and UCLA Biosafety Committee protocol BUA-2020-015-004-A. Post-mortem tissues were collected by Cedars-Sinai Biobank and Translational Research core in accordance with protocol Pro00036514.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll analysis and plotting scripts in R are available on github.com at github.com/Sareen-Lab/COVID.